Lynn Watkins Told the FDA About Chronic Pain, Facilitated Touch, and Psychedelic Delivery, Not the Misattributed Reuters Quote

Lynn Watkins used her two minutes at the FDA's September 14, 2026 hearing on psychedelic therapies to discuss chronic pain, her recovery from complex regional pain syndrome, and the role of neurorehabilitation, facilitated touch, neuromodulation, and physical therapy during active dosing. Her testimony drew on treatment with psilocybin and REMAP Therapeutics, including the reported return of movement in her right foot and toes within 90 minutes of dosing after nine years. Reuters correctly identified Watkins and her connection to chronic pain advocacy but attributed to her a widely circulated statement about approval not guaranteeing access that was made by another speaker. The correction matters because the misattribution displaced Watkins's argument that psychedelic delivery for pain may require approaches beyond psychiatry, while inaccurate wire copy can persist across syndicated coverage and search results. The piece also urges people to submit comments to the FDA docket before October 5, 2026.